Cargando…

Genetic Heterogeneity of Esophageal Squamous Cell Carcinoma with Inherited Family History

BACKGROUND: Esophageal squamous cell carcinoma (ESCC) is a common malignant tumor with significant geographical variation and familial aggregation. However, the potentially different mechanisms underlying tumorigenesis in patients with ESCC with and without a family history of the disease remain unc...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Wenwu, Leng, Xuefeng, Yang, Yanyu, Peng, Lin, Shao, Yang, Li, Xue, Han, Yongtao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481280/ https://www.ncbi.nlm.nih.gov/pubmed/32943884 http://dx.doi.org/10.2147/OTT.S262512

Ejemplares similares

Moderately differentiated esophageal squamous cell carcinoma has a poor prognosis after neoadjuvant chemoradiotherapy
por: He, Wenwu, et al.
Publicado: (2021)

The impact of adjuvant therapy on survival for node-negative esophageal squamous cell carcinoma: a propensity score-matched analysis
por: Deng, Xuyang, et al.
Publicado: (2021)

The efficacy and safety of neoadjuvant immunotherapy in resectable locally advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis
por: He, Wenwu, et al.
Publicado: (2023)

Family history of esophageal cancer increases the risk of esophageal squamous cell carcinoma
por: Chen, Tiantian, et al.
Publicado: (2015)

Network and pathway-based analysis of genes associated with esophageal squamous cell carcinoma
por: He, Wenwu, et al.
Publicado: (2023)

Clinical value of folate receptor-positive circulating tumor cells in patients with esophageal squamous cell carcinomas: a retrospective study
por: Zhou, Qiang, et al.
Publicado: (2023)

A five-gene signature to predict the overall survival time of patients with esophageal squamous cell carcinoma
por: He, Wenwu, et al.
Publicado: (2019)

Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study
por: He, Wenwu, et al.
Publicado: (2022)

Development and Validation of a Recurrence-Free Survival Prediction Model for Locally Advanced Esophageal Squamous Cell Carcinoma with Neoadjuvant Chemoradiotherapy
por: Zhou, Yehan, et al.
Publicado: (2023)

Resected lymph nodes and survival of patients with esophageal squamous cell carcinoma: an observational study
por: Li, Kexun, et al.
Publicado: (2023)

Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
por: He, Wenwu, et al.
Publicado: (2022)

Identification of tumor-infiltrating lymphocyte subpopulations correlated with patient prognosis in esophageal squamous cell carcinoma
por: Peng, Lin, et al.
Publicado: (2021)

The impact of intratumoral metabolic heterogeneity on postoperative recurrence and survival in resectable esophageal squamous cell carcinoma
por: Dong, Xinzhe, et al.
Publicado: (2017)

Impact of two‑field or three‑field lymphadenectomy on overall survival in middle and lower thoracic esophageal squamous cell carcinoma: A single‑center retrospective analysis
por: Li, Kexun, et al.
Publicado: (2023)

UBE2T Contributes to the Prognosis of Esophageal Squamous Cell Carcinoma
por: Wang, Xiaoyuan, et al.
Publicado: (2021)

MMS22L Expression as a Predictive Biomarker for the Efficacy of Neoadjuvant Chemoradiotherapy in Oesophageal Squamous Cell Carcinoma
por: Luo, Qiyu, et al.
Publicado: (2021)

GWAS follow-up study of esophageal squamous cell carcinoma identifies potential genetic loci associated with family history of upper gastrointestinal cancer
por: Song, Xin, et al.
Publicado: (2017)

EUS–derived maximum tumor thickness and tumor shrinkage rate as independent prognostic factors in locally advanced esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy
por: Chen, Xue, et al.
Publicado: (2023)

The current state of artificial intelligence in endoscopic diagnosis of early esophageal squamous cell carcinoma
por: Pan, Yuwei, et al.
Publicado: (2023)

Biological Significance of Tumor Heterogeneity in Esophageal Squamous Cell Carcinoma
por: Lin, Lehang, et al.
Publicado: (2019)

MET overexpression and intratumor heterogeneity in esophageal squamous cell carcinoma
por: Abboud, H.S., et al.
Publicado: (2021)

miRNA-9 Inhibits Proliferation and Migration of Lung Squamous Cell Carcinoma Cells by Regulating NRSF/EGFR
por: Wang, Kangning, et al.
Publicado: (2020)

Spatial intratumor heterogeneity of genetic, epigenetic alterations and temporal clonal evolution in esophageal squamous cell carcinoma
por: Hao, Jia-Jie, et al.
Publicado: (2016)

Heterogeneity of p53 Mutational Status in Esophageal Squamous Cell Carcinoma
por: Kuwabara, Shirou, et al.
Publicado: (1998)

Clonal Heterogeneity in Human Esophageal Squamous Cell Carcinomas on DNA Analysis
por: Hori, Hikaru, et al.
Publicado: (1996)

Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma
por: Yan, Ting, et al.
Publicado: (2019)

Prognostic impact of family history of cancer in Southern Chinese patients with esophageal squamous cell cancer
por: Su, Zhen, et al.
Publicado: (2019)

Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study
por: Jiang, Li, et al.
Publicado: (2022)

Integrated single-cell transcriptome analysis reveals heterogeneity of esophageal squamous cell carcinoma microenvironment
por: Dinh, Huy Q., et al.
Publicado: (2021)

Correction to: Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study
por: Jiang, Li, et al.
Publicado: (2023)

Heterogeneity of T3 stage esophageal squamous cell carcinoma in different parts based on enhanced CT radiomics
por: Li, Xiao-feng, et al.
Publicado: (2020)

Influences of intratumoral heterogeneity on assessment of tumor microenvironment in esophageal squamous cell carcinoma
por: Sugawara, Kotaro, et al.
Publicado: (2022)

Prognostic significance and postoperative chemoradiotherapy guiding value of mean platelet volume for locally advanced esophageal squamous cell carcinoma patients
por: Zhang, Wei, et al.
Publicado: (2023)

Novel genetic locus at MHC region for esophageal squamous cell carcinoma in Chinese populations
por: Zhang, Peng, et al.
Publicado: (2017)

Esophageal luminal stenosis is an independent prognostic factor in esophageal squamous cell carcinoma
por: Yang, Yu-Shang, et al.
Publicado: (2017)

Author Correction: Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma
por: Yan, Ting, et al.
Publicado: (2020)

Inter-evaluator heterogeneity of clinical diagnosis for locally advanced esophageal squamous cell carcinoma
por: Hamamoto, Yasuo, et al.
Publicado: (2017)

Efficacy and safety of neoadjuvant immunotherapy in resectable esophageal or gastroesophageal junction carcinoma: A pooled analysis of prospective clinical trials
por: Zhu, Jie, et al.
Publicado: (2022)

Heterogeneity Analysis of Esophageal Squamous Cell Carcinoma in Cell Lines, Tumor Tissues and Patient-Derived Xenografts
por: Ma, Fayang, et al.
Publicado: (2021)

Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study
por: Yang, Peng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_al91u6bj1ut6hnjghformdc1bp